Mesenchymal stromal cell-based therapy for cartilage regeneration in knee osteoarthritis

Xiang, Xiao-Na; Zhu, Si-Yi; He, Hong-Chen; Yu, Xi; Xu, Yang; He, Cheng-Qi

doi:10.1186/s13287-021-02689-9

Stem Cell Research & Therapy

Table 3 Characteristics of clinical trials about mesenchymal stromal cell-based therapy for cartilage regeneration in knee osteoarthritis

From: Mesenchymal stromal cell-based therapy for cartilage regeneration in knee osteoarthritis

Design	Sample size	Source	Dosage (cells)	Control intervention	Phase of trial	K-L grade	Outcomes	Follow-up	References
RCT	30	BM-MSCs	4 × 10⁷	HA	II	II-IV	MRI, WOMAC, VAS, Lequesne index	12 months	[157]
RCT and observational study	18	AT-MSCs	1, 2, 5 × 10⁷	None	I/IIa	> II	AE, WOMAC, NRS, SF- 36, MRI	24 months	[170]
Observational study	15	BM-MSCs	4 × 10⁷	None	I/II	II-III	AE, WOMAC, VAS, Lequesne index SF- 36, MRI	12 months	[158]
Observational study	18	AT-MSCs	2, 10, 50 × 10⁶	None	I	III-IV	AE, WOMAC, VAS, KOOS	6 months	[171]
Observational study	12	BM-MSCs	4 × 10⁷	None	II	II-IV	MRI, WOMAC, VAS, SF-36	12 months	[159]
RCT	26	UC-MSCs	2 × 10⁷	HA	I/II	I-III	MRI, WOMAC	12 months	[15]
RCT	24	AT-MSCs	1 × 10⁸	Saline	IIb	II-IV	MRI, WOMAC, KOOS	6 months	[19]
RCT	30	BM-MSCs	1, 10 × 10⁷	HA	I/II	> II	MRI, WOMAC, VAS	12 months	[160]
RCT	60	BM-MSCs	1 × 10⁸	PRP	II	> II	MRI, WOMAC, VAS	12 months	[161]
Observational study	25	AT-MSCs	1.89 × 10⁶	PRP, arthroscopic debridement	II	I-III	Lysholm, Tegner activity scale, VAS	16 months	[172]
RCT	20	Placenta-derived MSCs	5–6 × 10⁷	Saline	II	II-IV	VAS, KOOS, ROM, MRI	6 months	[176]
Observational study	18	AT-MSCs	1, 5, 10 × 10⁷	None	I/II	> II	WOMAC, MRI, arthroscopy	6 months	[173]
RCT	140	BM-MSCs	1.56 × 10⁴	TKA	III	II-IV	Radiographs, MRI	15 years	[162]
RCT	60	BM-MSCs	25, 50, 75, 150 × 10⁶	HA	I/II	II-III	WOMAC, VAS	12 months	[163]
RCT	30	AT-MSCs	1 × 10⁸	Conservative management	II	II-III	AE, MRI, KOOS, WOMAC, NRS	12 months	[18]
RCT	43	BM-MSCs	4 × 10⁷	Saline	I/II	II-IV	VAS, WOMAC	6 months	[164]
Observational study	29	UC-MSCs	1 × 10⁷	HA	II	I-II	WOMAC	6 months	[175]
Observational study	4	BM-MSCs	8–9 × 10⁶	None	I	NR	VAS, X-ray, activities	12 months	[165]
Observational study	12	AT-MSCs	5 × 10⁷	None	I	NR	AE, MRI	12 months	[174]
Observational study	12	BM-MSCs	1, 10, 50 × 10⁶	None	I/IIa	III-IV	ROM, KOOS, WOMAC, MRI	12 months	[166]
RCT	18	BM-MSCs	NR	PRP	II	II-IV	KOOS, ROM	12 months	[167]
RCT	57	BM-MSCs	NR	PRP	II	II-IV	KOOS, ROM	12 months	[168]
Observational study	12	BM-MSCs	6 × 10⁷	None	I	II-III	AE, KOOS, MRI	24 months	[169]

RCT Randomized controlled trial, MSCs mesenchymal stromal cells, BM bone marrow, AT adipose tissue, NR not reported, AE adverse event, NRS numerical pain rating scale, VAS visual analog scale, WOMAC Western Ontario and McMaster Universities Osteoarthritis Index, SF-36 short-form 36 health survey questionnaire, KOOS Knee Injury and Osteoarthritis Outcome Score, MRI magnetic resonance imaging, TKA total knee arthroplasty, HA hyaluronic acid, PRP platelet-rich plasma, K-L Kellgren-Lawrence

Back to article page

ISSN: 1757-6512

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com